About Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1
Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 (HCN1) is a protein
from Homo sapiens identified by UniProt accession
O60741, 890 residues long.
MolForge cross-references it against 0 known binders and
385 disease associations.
Target properties
| Protein name | Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 |
|---|
| UniProt accession | O60741 |
|---|
| Gene | HCN1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 890 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (2)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (385)
Diseases linked to this target (Open Targets).
- Generalized epilepsy with febrile seizures-plus · score 0.78
- undetermined early-onset epileptic encephalopathy · score 0.73
- developmental and epileptic encephalopathy · score 0.55
- schizophrenia · score 0.43
- breast carcinoma · score 0.41
- Seizure · score 0.38
- generalized epilepsy with febrile seizures plus · score 0.37
- feeling "fed-up" measurement · score 0.37
- P wave duration · score 0.36
- PR interval · score 0.36
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O60741-F1 | alphafold | PREDICTED | 68.91 | — |
Amino-acid sequence (890 residues)
MEGGGKPNSS SNSRDDGNSV FPAKASATGA GPAAAEKRLG TPPGGGGAGA KEHGNSVCFK VDGGGGGGGG GGGGEEPAGG FEDAEGPRRQ YGFMQRQFTS MLQPGVNKFS LRMFGSQKAV EKEQERVKTA GFWIIHPYSD FRFYWDLIML IMMVGNLVII PVGITFFTEQ TTTPWIIFNV ASDTVFLLDL IMNFRTGTVN EDSSEIILDP KVIKMNYLKS WFVVDFISSI PVDYIFLIVE KGMDSEVYKT ARALRIVRFT KILSLLRLLR LSRLIRYIHQ WEEIFHMTYD LASAVVRIFN LIGMMLLLCH WDGCLQFLVP LLQDFPPDCW VSLNEMVNDS WGKQYSYALF KAMSHMLCIG YGAQAPVSMS DLWITMLSMI VGATCYAMFV GHATALIQSL DSSRRQYQEK YKQVEQYMSF HKLPADMRQK IHDYYEHRYQ GKIFDEENIL NELNDPLREE IVNFNCRKLV ATMPLFANAD PNFVTAMLSK LRFEVFQPGD YIIREGAVGK KMYFIQHGVA GVITKSSKEM KLTDGSYFGE ICLLTKGRRT ASVRADTYCR LYSLSVDNFN EVLEEYPMMR RAFETVAIDR LDRIGKKNSI LLQKFQKDLN TGVFNNQENE ILKQIVKHDR EMVQAIAPIN YPQMTTLNST SSTTTPTSRM RTQSPPVYTA TSLSHSNLHS PSPSTQTPQP SAILSPCSYT TAVCSPPVQS PLAARTFHYA SPTASQLSLM QQQPQQQVQQ SQPPQTQPQQ PSPQPQTPGS STPKNEVHKS TQALHNTNLT REVRPLSASQ PSLPHEVSTL ISRPHPTVGE SLASIPQPVT AVPGTGLQAG GRSTVPQRVT LFRQMSSGAI PPNRGVPPAP PPPAAALPRE SSSVLNTDPD AEKPRFASNL
Explore Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets